Consistent with effects seen in multiple clinical trials in patients with type 2 diabetes (23), in the current study, SGLT2 inhibitor treatment improved glucose control in the obese Zucker rat. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.